

San Antonio Breast Cancer Symposium (SABCS) 2014

Studies from US Oncology Research, The US Oncology Network
and McKesson Specialty Health Affiliated Investigators

Henry B. Gonzalez Convention Center, San Antonio, TX, Dec. 9-13, 2014

Posters		
Authors	Title	Poster #
Diab S , Rodriguez P, Leininger A, Clark L, Janicek MF, Smith EB, Sandbach J, Saam J, Langer L.	Experience in the community oncology practice with a 25-gene hereditary cancer panel	P1-03-03
Espina V, Levin MK, Carpten JD, Craig DW, Von Hoff D , Liotta LA, O'Shaughnessy J.	Triple negative breast cancer metastases: Protein signal transduction networks within the tumor-stromal microenvironment complement genomic analysis and stratify local versus distant metastasis	P1-07-05
Cherni I, Levin MK, O'Shaughnessy J , Carpten J.	Comparative analysis of somatic mutations in matched primary vs metastatic triple-negative breast cancers	P2-03-04
Palma NA, Chmielecki J, Frampton G, Ali S, Levin MK, Ross JS, Morosini D, Palmer G, Miller VA, Stephens P, O'Shaughnessy J.	FoundationOne Profiling of TSC1 and TSC2-Mutated Advanced Breast Cancers	P2-03-06
Mayer M, Coons HL, Jones S , Percassi D.	Understanding potential gaps in treatment discussions between caregivers/patients with advanced breast cancer and oncologists	P2-10-08
Fisher RE, Stenhouse M, Lai-O'Connell A.	The curriculum for recovery, a five week educational and experiential support group for breast cancer survivorship recovery	P2-12-04
Millis SZ, Xiu J, Gatalica Z, O'Shaughnessy J.	Multiplatform molecular profiling of male BC reveals significant differences in actionable targets from matched female breast carcinomas	P3-06-17
Gunn S, Zien A, Hartenfeller M, Diella F, Brock S, Stein M, Badbanchi S, Doerks A, Jackson D, Asmar L, Wang Y, Jones S.	Identification of ERBB2 gene variants in HER2 positive disease associated with trastuzumab response in an adjuvant trastuzumab chemotherapy trial	P3-06-22
Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman P, Mason G, Mayer M, O'Shaughnessy J , Rugo H, Swain SM, Yardley DA, Beattie M, Yoo B, Hurvitz S.	Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study	P3-07-14

Bolded text: US Oncology Network Investigator

Posters		
Authors	Title	Poster #
Smith JW, Vukelja S, Hoffman A, Jones V, McIntyre K, Berrak E, Teng A, Cox D, O'Shaughnessy J.	Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER+ early-stage breast cancer: A phase 2, multicenter, open-label study using 2 different dosage regimens	P3-09-09
Perez EA, Caygill K, Hannah AL, Cortes J, Awada A, O'Shaughnessy J , Twelves C, Rugo H, Im S-A, Anderes K, Davis DW, Hoch U.	Etirinotecan pegol target-specific pharmacodynamic biomarkers in circulating tumor cells from patients with metastatic breast cancer in the Phase 3 BEACON study	P3-10-03
Holmes FA, McIntyre KJ, Krop IE, Osborne CR, Smith II JW, Modiano MR, Gupta M, Downey LB, Nanda R, Saleh MN, Young JR, Horgan KE, Kubasek W, MacBeath G, Danso MA, O'Shaughnessy J.	A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative Breast Cancer	P3-11-03
Blum JL , Garby CA, Simmons AE, Walker SA, Panos LE.	Results of next-generation sequencing panels in a large community-based hereditary cancer risk program	P4-12-06
Hamlington B, Sedlacek S, Langer L , Goetsch B, Lemas K, Diab S.	Utilizing next generation sequencing technologies for hereditary breast cancer risk assessments in a private oncology practice	P4-12-08
Gunn S, McCaskill C, Daley L, Puskas A, Asmar L, Wang Y, Jones S.	The chromosomal genomic landscape and targetable co-amplified genes in HER2 positive breast cancer patients who relapsed on an adjuvant trastuzumab chemotherapy trial	P5-10-18
Schwartzberg L, McIntyre K, O'Shaughnessy J , Glück S, Berrak E, Song J, Cox D, Vahdat L.	Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC	P5-17-02
Schwartzberg L, Wilks S , Puhalla S, O'Shaughnessy J , Berrak E, Song J, Cox D, Vahdat L.	Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer	P5-17-03
Traina TA, O'Shaughnessy J , Cortes J, Peterson A, Tudor C, Steinberg JL, Hudis C, Schmid P, Yardley DA.	Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)	P5-19-09
Traina TA, O'Shaughnessy J , Nanda R, Schwartzberg L, Abramson V, Cortes J, Peterson A, Tudor IC, Blaney M, Steinberg JL, Kelly C, Trudeau M, Awada A, Winer E, Hudis C, Schmid P, Yardley DA	Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)	P5-19-07
Habib JG, Espirito J, Harrell R, Turnwald B, O'Shaughnessy J, Epstein E, Patt D.	Vitamin D levels, triple-negative breast cancer, and geography: A retrospective analysis of a large database of oncology practices in the United-States (US)	P6-09-02
Pierobon M, Anthony SP, Reeder A, Nicholas Robert , D. Northfelt, M. Jahanzeb, Vocila L, Wulfkuhle J, Dunetz B, Liotta , Petricoin E.F.	Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: Implications for patient stratification to targeted treatment	P1-07-23
Litton JK, Blum JL , Eiermann W, Im Y-H, Martin M, Mina L, Roché H, Rugo HS, Visco F, Zhang C, Lokker NA, Lounsbury DL	A Phase 3, Open-Label, Randomized, Parallel, 2-Arm Multi-Center Study of the Oral PARP inhibitor BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer (EMBRACA)	OT1-1-12
Yardley DA, Coleman RE, Conte P, O'Shaughnessy J , Cortes J, Glück S, Brufsky A, Nabholz J-MA, Li L, Miller J, Barton D, Harbeck N,	tnAcity: phase II/III trial of <i>nab</i> -paclitaxel (<i>nab</i> -P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)	OT2-2-01

Poster Discussion		
Authors	Title	Poster Discussion #
Rugo HS, Tredan O, Ro J, Morales S, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL , Eaton L, Gause CK, Wang A, Im E, Mauro DJ, Baselga J.	Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer	PD5-1
Palma NA, Ali S, Frampton G, Wang K, Gilmore H, Peguero J, Harris LN, Cristofanilli M, Chmielecki J, Ross JS, Morosini D, Miller VA, Stephens PJ, Palmer G, O'Shaughnessy J.	Profiling of ESR1-mutated metastatic breast cancers by FoundationOne allows a broad genomic understanding for potential clinical implications	PD6-5

Bolded text: US Oncology Network Investigator

Learn More Today

To learn more about US Oncology Research, please contact us.

For Pharmaceutical & Biotech customers:

call 866.951.2774, email us at USOncologyResearch@mckesson.com,
or visit www.MckessonSpecialtyHealth.com/PharmaBiotech

For Providers:

call 800.482.6700, option 4, email us at msh.providers@mckesson.com,
or visit www.usoncology.com